ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd., commonly referred to as ASKA Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan. Founded in 1941, the company has established a strong presence in various operational regions, including Asia and beyond. ASKA Pharma focuses on the development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of neurology, urology, and oncology. With a commitment to research and development, ASKA Pharma has achieved significant milestones, including the introduction of unique therapeutic solutions that address unmet medical needs. The company is recognised for its high-quality products, which are distinguished by their efficacy and safety profiles. ASKA Pharma's dedication to advancing healthcare has solidified its position as a trusted name in the pharmaceutical sector, contributing to improved patient outcomes globally.
DitchCarbon Score
How does ASKA Pharmaceutical Holdings Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ASKA Pharmaceutical Holdings Co., Ltd.'s score of 31 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ASKA Pharmaceutical Holdings Co., Ltd.'s reported carbon emissions
In 2023, ASKA Pharmaceutical Holdings Co., Ltd. reported total carbon emissions of approximately 6,055,000 kg CO2e for Scope 1 and about 2,949,000 kg CO2e for Scope 2. This reflects a decrease from 2022, where emissions were approximately 6,687,000 kg CO2e for Scope 1 and about 4,093,000 kg CO2e for Scope 2. The company has not disclosed any Scope 3 emissions data. Despite these figures, ASKA Pharmaceutical has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of formal reduction commitments suggests a need for further development in their climate strategy. Overall, ASKA Pharmaceutical's emissions data indicates a positive trend in reducing Scope 1 and Scope 2 emissions, but the lack of comprehensive climate commitments highlights an area for potential growth in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 6,687,000 | 0,000,000 |
| Scope 2 | 4,093,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ASKA Pharmaceutical Holdings Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
